# Coronavirus Disease Biology and Previous Therapeutic Efforts

---

## List of SARS/MERS Genes and their functions 

This figure from the "Coronaviruses — drug discovery and therapeutic options" (A. Zumla et al., 2016) review article describes the genome of SARS-CoV and MERS-CoV. The proteins targets are separated into two different categories: Non-structural and structural. There are four targets listed with  effort for each category of protein.

![Figure_ CoV](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_targets2016fig1.jpg)

Additionally, Figure 2 of the same review article shows the virus-based and host-based therapeutic options within the cell. This figure visualizes host and viral targets and illustrates their functions.

![Download Full Image](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_targets2016fig2.png)


## List of therapeutics for SARS/MERS to target viral or host biological system and related vaccine efforts. 

This information comes from Table 2 of the review article by A. Zumla et al., 2016. 

### Targeting Virus

| Targeted Viral components                          | Potential therapeutics |
| -------------------------------------------------- | ---------------------- |
| Nucleosides or Nucleotides                         | Mycophenolic Acid      |
| Base Sequence GUC in <br />loop region of CoV mRNA | Ribozyme               |
| Viral Replication complex                          | K22                    |
| Long Viral dsRNA                                   | DRACO                  |
| PLpro                                              | GRL0617                |
| 3CLpro                                             | Lopinavir              |
| RdRp                                               | Ribavirin, BCX4430,    |
| Helicase                                           | Bananins, SSYA10-001   |
| RBD of S1 Subunit of S protein                     | NERS-4, MERS-27        |
|S2 subunit of S                                     | HR2P and P1 peptides   |
|Oligosaccharides onS                                |  Griffithsin           |
|S expression|siRNA*|
|E | siRNA*, Hexamethylene amiloride|
|M | siRNA*|
|N | PJ34, intrabodies‡ and siRNA*|
|Accessory proteins| siRNA* |
|Lipid membrane| LJ001 and JL103|

### Targeting Host

| Targeted host factors                  | Potential Therapeutics                                       |
| -------------------------------------- | ------------------------------------------------------------ |
| Interferon Response                    | Recombinant interferons(interferon alfa, interferon beta, interferon gamma), Poly(I:C), Nitazoxanide             |
| Cyclophilins                           | Cyclosporine, alisporivir                                    |
| Kinase signalling pathways             | Trametinib, selumetinib, everolimus, <br /> rapacycin, dasatinib, imatinib |
| ACE2                                   | P4 and P5 peptides, NAAE                                     |
| DPP4                                   | anti-DPP4 mAb                                                |
| Endosomal protease (cathepsins)        | E64D, K11777, small molecule 5705213                         |
| Surface Protease (TMPRSS2)             | Camostat mesylate                                            |
| Other host proteases (furin)           | dec-RVKR-CMK                                                 |
| Clathrin-mediated endocytosis (ATP1A1) | Chlorpromazine, Ouabain, bufalin                             |
| Endosomal acidification                | Chloroquine                                                  |

### Vaccine 

| Vaccine Type                           | Examples                                                     |
| -------------------------------------- | ------------------------------------------------------------ |
| Live attenuated virus                  | rMERS‐CoV‐ΔE            |
| DNA plasmid                          | MERS‐CoV S DNA |
| Viral vectors            | MVA‐MERS‐S, Ad5‐MERS‐S, Ad5‐MERS‐S1, Ad5‐S and Ad41‐S |
| Nanoparticles                                  | MERS‐CoV S‐containing nanoparticles                   |
| Virus‐like particles                                   | VRP‐S                                         |
| Recombinant protein subunits       | S(RBD)‐Fc, S1(358–588)‐Fc, S(377–588)‐Fc and rRBD                 |


## Biological Processes of coronavirus infection

The targetscape of SARS virus within the cell is provided by [Clarivate Analytics](http://clarivate.com.cn/coronavirus-resources/drug031.htm)

![sars1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_target_sars.png)

The targetscape of MERS virus within the cell is provided by [Clarivate Analytics](http://clarivate.com.cn/coronavirus-resources/drug031.htm), is shown below.

![mers1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_target_mers.png)

The targetscape of nCov provided by [Clarivate Analytics](http://clarivate.com.cn/coronavirus-resources/drug031.htm), is also shown below.

![ncov1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_target_ncov.jpg)

---

## List of Host Targets related to SARS 

A list of human targets related to SARS coronavirus is provided by [Genecards](https://www.genecards.org) using a keyword search query: [Link](https://www.genecards.org/Search/Keyword?queryString=SARS)

Top 30 relevant host targets predicted for SARS

|  ﻿Gene Symbol  | Description  | Category  | Gifts  | GC Id  | Relevance score  | GeneCards Links  | 
| ---- | --- | --- | --- | --- | --- | --- | 
|  ACE2  | Angiotensin I Converting Enzyme 2  | Protein Coding  | 48  | GC0XM015494  | 37.3  | [ACE2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ACE2)  | 
|  CLEC4M  | C-Type Lectin Domain Family 4 Member M  | Protein Coding  | 39  | GC19P007763  | 24.28  | [CLEC4M](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLEC4M)  | 
|  CD209  | CD209 Molecule  | Protein Coding  | 42  | GC19M007739  | 23.22  | [CD209](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD209)  | 
|  TMPRSS2  | Transmembrane Serine Protease 2  | Protein Coding  | 42  | GC21M041464  | 22.23  | [TMPRSS2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMPRSS2)  | 
|  IFNA1  | Interferon Alpha 1  | Protein Coding  | 39  | GC09P021478  | 22.2  | [IFNA1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFNA1)  | 
|  CXCL10  | C-X-C Motif Chemokine Ligand 10  | Protein Coding  | 43  | GC04M076021  | 21.68  | [CXCL10](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL10)  | 
|  IFNG  | Interferon Gamma  | Protein Coding  | 48  | GC12M068064  | 21.54  | [IFNG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFNG)  | 
|  TNF  | Tumor Necrosis Factor  | Protein Coding  | 52  | GC06P033397  | 21.25  | [TNF](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNF)  | 
|  CCL5  | C-C Motif Chemokine Ligand 5  | Protein Coding  | 43  | GC17M035871  | 20.58  | [CCL5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CCL5)  | 
|  IL6  | Interleukin 6  | Protein Coding  | 49  | GC07P022765  | 20.04  | [IL6](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL6)  | 
|  IFNB1  | Interferon Beta 1  | Protein Coding  | 41  | GC09M021077  | 19.99  | [IFNB1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IFNB1)  | 
|  CXCL8  | C-X-C Motif Chemokine Ligand 8  | Protein Coding  | 42  | GC04P073740  | 19.88  | [CXCL8](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL8)  | 
|  CCR5  | C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)  | Protein Coding  | 47  | GC03P046384  | 19.41  | [CCR5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CCR5)  | 
|  CD40LG  | CD40 Ligand  | Protein Coding  | 47  | GC0XP136649  | 19.35  | [CD40LG](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD40LG)  | 
|  SH2D3A  | SH2 Domain Containing 3A  | Protein Coding  | 35  | GC19M006752  | 19.33  | [SH2D3A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SH2D3A)  | 
|  MX1  | MX Dynamin Like GTPase 1  | Protein Coding  | 41  | GC21P041420  | 19.09  | [MX1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MX1)  | 
|  CCL2  | C-C Motif Chemokine Ligand 2  | Protein Coding  | 49  | GC17P034255  | 18.9  | [CCL2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CCL2)  | 
|  CXCL9  | C-X-C Motif Chemokine Ligand 9  | Protein Coding  | 38  | GC04M076001  | 18.82  | [CXCL9](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CXCL9)  | 
|  GPT  | Glutamic--Pyruvic Transaminase  | Protein Coding  | 41  | GC08P144502  | 18.7  | [GPT](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GPT)  | 
|  CTSL  | Cathepsin L  | Protein Coding  | 46  | GC09P087725  | 18.4  | [CTSL](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CTSL)  | 
|  IL10  | Interleukin 10  | Protein Coding  | 47  | GC01M206767  | 18.29  | [IL10](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL10)  | 
|  IRF3  | Interferon Regulatory Factor 3  | Protein Coding  | 47  | GC19M049659  | 18.24  | [IRF3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IRF3)  | 
|  MBL2  | Mannose Binding Lectin 2  | Protein Coding  | 47  | GC10M052760  | 18.07  | [MBL2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MBL2)  | 
|  IL2  | Interleukin 2  | Protein Coding  | 46  | GC04M122451  | 17.97  | [IL2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL2)  | 
|  TMPRSS11D  | Transmembrane Serine Protease 11D  | Protein Coding  | 38  | GC04M067820  | 17.25  | [TMPRSS11D](https://www.genecards.org/cgi-bin/carddisp.pl?gene=TMPRSS11D)  | 
|  STAT1  | Signal Transducer And Activator Of Transcription 1  | Protein Coding  | 53  | GC02M190964  | 17.16  | [STAT1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=STAT1)  | 
|  SARS1  | Seryl-TRNA Synthetase 1  | Protein Coding  | 35  | GC01P109214  | 17.1  | [SARS1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SARS1)  | 
|  FURIN  | Furin, Paired Basic Amino Acid Cleaving Enzyme  | Protein Coding  | 47  | GC15P090868  | 17.05  | [FURIN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=FURIN)  | 
|  CRP  | C-Reactive Protein  | Protein Coding  | 46  | GC01M159715  | 16.85  | [CRP](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CRP)  | 

---
## List of experimentally verified coronavirus-host interactions 

82 coronavirus-human interactions with experimental evidence are provided by [PHISTO](http://www.phisto.org/), involving 33 human proteins and 21 coronavirus proteins.

[Data Download](https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/Corona_human_interaction.csv) 
